Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4194838 | 0.85 | CRHR1 (0.32) | TERTCTSLCRHR1 | |
| SCHEMBL4188323 | 0.84 | BACE1 (0.39) | ALDH1A1BCHEFFAR2TRPV1S1PR1 | |
| SCHEMBL4189946 | 0.81 | ALDH1A1 (0.40) | TERTGRIA2GRIN2AKDM4EALDH1A1 | |
| SCHEMBL11947602 | 0.78 | GPBAR1 (0.35) | GRIA2GRIN2A | |
| SCHEMBL4190187 | 0.76 | CSF1R (0.31) | FFAR2CRHR1CSF1R | |
| SCHEMBL4186096 | 0.73 | CETP (0.34) | GRIA2GRIN2ACTSL | |
| SCHEMBL4509933 | 0.71 | CRHR1 (0.45) | CYP2D6CRHR1 | |
| SCHEMBL4223794 | 0.69 | TRPM8 (0.43) | KDM4EFFAR2CRHR1CSF1R | |
| SCHEMBL11947609 | 0.69 | L3MBTL1 (0.40) | KDM4EALDH1A1S1PR1OPRK1CRHR1 | |
| SCHEMBL4346805 | 0.69 | L3MBTL1 (0.40) | KDM4EALDH1A1S1PR1OPRK1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| EP-2024356-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | Novartis AG (CH) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | CETP, LCAT, CES1 | TERT 851/4885GRIA2 4659/4885GRIN2A 4807/4885 |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | CETP, LCAT, CES1 | TERT 851/4885GRIA2 4659/4885GRIN2A 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.